Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06453642 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of a Simple-Prep Controlled Embolic

Study acronym: GPX
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 30, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. 2 versions Re-verified since Mar 4, 2026, no change to tracked fieldsv18-v19
  2. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 20 of 20 sites
    v17
  3. Study sites: 19 to 20v16
  4. Study sites: 18 to 19v15
  5. Study sites: 17 to 18v14
Show 12 earlier versionsHide 12 earlier versions
  1. Study sites: 16 to 17v13
  2. Study sites: 15 to 16v12
  3. Study sites: 12 to 15v11
  4. Study sites: 11 to 12v10
  5. Study sites: 10 to 11v9
  6. Study sites: 9 to 10v8
  7. Study sites: 8 to 9v7
  8. Study sites: 7 to 8v6
  9. Study sites: 5 to 7v5
  10. Study sites: 1 to 5
    • Primary completion date: Feb 2026 to May 2026
    • Study completion date: Jun 2026 to Sep 2026
    • Start date changed from estimate of Sep 2024 to Nov 18, 2024
    v4
  11. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v3
  12. Start date: Jun 2024 to Sep 2024v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The objective of this study is to evaluate the safety and effectiveness of the GPX® Embolic Device when used as indicated for embolization requiring distal vessel penetration in 114 subjects in up to 25 investigational sites in the USA, New Zealand, and Canada.
Trial Details
NCT Number NCT06453642
Lead Sponsor Fluidx Medical Technology, Inc.
Collaborators: Bright Research Partners
Conditions
(from sponsor)		 Embolization, Vascular Tumor, Renal Angiomyolipoma, Renal Cell Carcinoma, Bone Tumor, Portal Vein Embolization
Related terms Angiomyolipoma, Bone Neoplasms, Carcinoma, Renal Cell, Vascular Neoplasms
Enrollment 114 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov